However, our sequencing result reveals that patients with high PRFT had increased angiogenesis gene signatures which might enhance drug delivery and improve the patient’s response to anti-VEGF therapy in RCC. The gene discussed is VEGFA; the disease is renal cell adenocarcinoma.